An article published in the June issue of the Journal of the American Medical Association spotlights value-based pricing models for drugs.
The article, penned by Anna Kaltenboeck and Peter Bach, both of the Center for Health Policy and Outcomes at the Memorial Sloan Kettering Cancer Center, says the pricing paradigm has seen broad support, including endorsements by the National Academies of Science, Engineering and Medicine; the American Medical Association; and the President’s Cancer Panel.
Increased momentum toward value-based designs is rooted toward increasing drug costs.
“The current system, in which prices reflect ‘what the market will bear,’ has been plagued by price hikes on legacy drugs and wide dissociations between prices of drugs and their benefits,” the authors write.
Click here to read the full article on JAMA. (Paid subscription required)
